Skip to content

Gilead Sciences Inc Price, Chart & Factor Exposure

Free Data & Analytics Access

Latest earnings: October 29, 2026 results vs estimates

Gilead Sciences Inc · E.GILD.NASDAQ · United States
Use symbol E.GILD.NASDAQ in our API & Excel add-in to retrieve this data ↓
165.61
(+0.04%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 100%
Trend 100%
Bubble Risk LOW
Realised Volatility (20D) 30.36%

Gilead Sciences Inc Forecast

Gilead Sciences Inc short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 30.4% a year, a typical one-standard-deviation range is 158.53–172.69 over a week, 151.10–180.12 over a month and 115.33–215.89 over a year. (Signals as of 1 Nov 2026.)

Gilead Sciences Inc Price Chart

MacroFinance.ai

Gilead Sciences Inc Factors

Test factors in Return analysis →
Market/MacroIndicatorNowChangeRange
Quantitative
Gilead Sciences Inc
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Gilead Sciences Inc
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Gilead Sciences Inc
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
Gilead Sciences Inc
P/S
6.69x
Stretched vs own history
QoQ +12.1%
YoY +22.5%
now 6.68585.19 low6.89 high
ⓘP/S As of 22 Nov 2026.See Gilead Sciences Inc returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
Gilead Sciences Inc
P/B
15.89x
Stretched vs own history
QoQ +3.5%
YoY +115.5%
now 15.89036.6 low16.41 high
ⓘP/B As of 22 Nov 2026.See Gilead Sciences Inc returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
Gilead Sciences Inc
EV/EBITDA
175.95x
Stretched vs own history
QoQ +54.8%
YoY +1,263.6%
now 175.947411.72 low180.86 high
ⓘEV/EBITDA As of 22 Nov 2026.See Gilead Sciences Inc returns when EV/EBITDA looked like now →Opens Return analysis with the filter EV/EBITDA within ±5% of today
Gilead Sciences Inc
EV/Sales
7.32x
Stretched vs own history
QoQ +9.0%
YoY +20.8%
now 7.32455.71 low7.53 high
ⓘEV/Sales As of 22 Nov 2026.See Gilead Sciences Inc returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
Gilead Sciences Inc
FCF Yield
6.7%
Mid-range vs own history
QoQ −6.7%
YoY +15.3%
now 6.65184.71 low7.82 high
ⓘFCF Yield As of 22 Nov 2026.See Gilead Sciences Inc returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
Gilead Sciences Inc
Earnings Yield
-1.9%
Weak vs own history
QoQ +4.5%
YoY −136.5%
now -1.8646-1.96 low5.94 high
ⓘEarnings Yield As of 22 Nov 2026.See Gilead Sciences Inc returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
Gilead Sciences Inc
Dividend Yield
2.0%
Weak vs own history
QoQ −11.6%
YoY −21.0%
now 1.97991.92 low2.64 high
ⓘDividend Yield As of 22 Nov 2026.See Gilead Sciences Inc returns when Dividend Yield looked like now →Opens Return analysis with the filter Dividend Yield within ±5% of today
Gilead Sciences Inc
Market Cap
$207.2B
Highest in 5 years
QoQ +14.1%
YoY +30.5%
now 207178.11150,982 low213,521 high
ⓘMarket Cap As of 22 Nov 2026.See Gilead Sciences Inc returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
Gilead Sciences Inc
Net Debt
$19.8B
Mid-range vs own history
QoQ −14.2%
YoY +12.5%
now 1979414,531 low23,067 high
ⓘNet Debt As of 22 Nov 2026.See Gilead Sciences Inc returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
Gilead Sciences Inc
Net Debt / EBITDA
15.34x
High vs own history
QoQ +19.8%
YoY +1,092.4%
now 15.34421 low15.34 high
ⓘNet Debt / EBITDA As of 22 Nov 2026.See Gilead Sciences Inc returns when Net Debt / EBITDA looked like now →Opens Return analysis with the filter Net Debt / EBITDA within ±5% of today
Gilead Sciences Inc
Current Ratio
1.38x
Mid-range vs own history
QoQ +9.0%
YoY −5.1%
now 1.37931.27 low1.97 high
ⓘCurrent Ratio As of 22 Nov 2026.See Gilead Sciences Inc returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
Gilead Sciences Inc
Quick Ratio
1.22x
Mid-range vs own history
QoQ +12.2%
YoY −6.7%
now 1.22131.09 low1.77 high
ⓘQuick Ratio As of 22 Nov 2026.See Gilead Sciences Inc returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
Gilead Sciences Inc
Interest Coverage
-1.51x
Weak vs own history
QoQ +56.9%
YoY −114.1%
now -1.5089-1.51 low11.68 high
ⓘInterest Coverage As of 22 Nov 2026.See Gilead Sciences Inc returns when Interest Coverage looked like now →Opens Return analysis with the filter Interest Coverage within ±5% of today
Gilead Sciences Inc
Debt / Equity
2.01x
High vs own history
QoQ −9.3%
YoY +73.8%
now 2.01190.94 low2.22 high
ⓘDebt / Equity As of 22 Nov 2026.See Gilead Sciences Inc returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
Gilead Sciences Inc
Piotroski F-Score
5
Weak vs own history
QoQ 0.0%
YoY −44.4%
now 55 low9 high
ⓘPiotroski F-Score As of 22 Nov 2026.See Gilead Sciences Inc returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
Gilead Sciences Inc
Altman Z-Score
3.93
Mid-range vs own history
QoQ +9.6%
YoY −4.2%
now 3.92863.33 low4.84 high
ⓘAltman Z-Score As of 22 Nov 2026.See Gilead Sciences Inc returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  18 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  21 members-only factors: Sloan Accruals, Cash-Earnings Gap, Beneish M-Score, Days Sales in Receivables Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for Gilead Sciences Inc, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Gilead Sciences Inc fundamentals: income statement, balance sheet & cash flow

Gilead Sciences Inc reported revenue of $29.44bn and net income of $8.51bn in FY2025, the year ended 31 December 2025 — revenue up 2.4% and net income up 1,672.9% on the prior year. Free cash flow was $9.46bn. These figures are as reported in the filings, not restated: 36 fiscal years and 145 quarters of history, back to December 1990. 173 FINRA short-interest settlements are published alongside them, back to June 2019.

Revenue (FY2025)
$29.44bn
+2.4%
Net income
$8.51bn
+1,672.9%
Gross margin
78.83%
Free cash flow
$9.46bn
-8.2%
Net debt
$17.37bn
Shares short (30 Oct 2026)
21.27m
3.18 days to cover
Gilead Sciences Inc income statement, annual, as reported · USD billions unless stated
USD billionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue29.4428.7527.1227.2827.31
Cost of revenue6.236.255.805.666.60
Gross profit23.2122.5027.1221.6220.70
Research & development5.805.915.724.984.60
Selling, general & admin.7.3914.93———
Operating income10.021.667.617.339.92
EBITDA13.584.437.618.8511.33
Interest expense1.020.980.940.941.00
Pre-tax income9.800.696.865.818.28
Income tax1.290.21-1.251.252.08
Net income8.510.485.674.596.23

Download Gilead Sciences Inc fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.GILD.NASDAQ&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks all 36 fiscal years and 145 quarters, the filing vintages behind each number and API access.
Create free account

Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.

Research on Gilead Sciences Inc

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Gilead Sciences Inc Trading Strategies

58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Gilead Sciences Inc; 28 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 58 strategies holding SPY, XLV →

Statistical Distribution of Returns

Plus

How Gilead Sciences Inc’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Gilead Sciences Inc behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Gilead Sciences Inc (United States)

Gilead Sciences Inc is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

More on Gilead Sciences Inc

Frequently asked questions

What is Gilead Sciences Inc?
Gilead Sciences Inc is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Gilead Sciences Inc price?
The latest close is 165.61 (1 Nov 2026), +0.04% on the day. The price at the top of the page refreshes during the trading day.
Is Gilead Sciences Inc in an uptrend?
As of 1 Nov 2026, short-term momentum is strongly positive (4 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly positive (8 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Gilead Sciences Inc?
20-day realised volatility is 30.4% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 8.8% over a month and 4.3% over a week.
What factors affect Gilead Sciences Inc?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Gilead Sciences Inc, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Gilead Sciences Inc?
58 backtested tactical asset allocation strategies trade Gilead Sciences Inc through SPY, XLV; 28 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Gilead Sciences Inc returns analysed?
The Statistical Distribution of Returns section shows the distribution of Gilead Sciences Inc daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Gilead Sciences Inc historical data?
In the Free historical data section of this page: the last 10 years of Gilead Sciences Inc daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Gilead Sciences Inc historical data (last 10 years)

Browse or instantly download the last 10 years of Gilead Sciences Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.GILD.NASDAQ&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-20166.43
2026-11-19166.53
2026-11-18168.98
2026-11-17170.26
2026-11-16167.58
2026-11-13168.08
2026-11-12167.95
2026-11-11169.73
2026-11-10170.87
2026-11-09169.32
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.